Microsporum canis is a zoophilic species, found to be the most frequently isolated species in animals. M. canis causes sporadic outbreaks of infections in humans, such as the one that occurred in Canada, where more than 1,000 human cases were detected over an 8-year period. Despite the medical importance of M. canis infections, there are limited in vitro data on the antifungal susceptibility to antifungal drugs, including new generation triazoles and imidazoles.The aim of the current study was to comprehensively evaluate the in vitro activity of new azoles and comparator drugs against a large panel of M. canis isolates collected in Iran, France, and Turkey from patients and animals with dermatophytosis using a microdilution assay.The in vitro susceptibility to novel triazoles and imidazoles was compared to that of other antifungal drugs using a large collection of M. canis clinical isolates (n = 208) obtained from patients and animals with dermatophytosis in Iran, France, and Turkey.All isolates exhibited high susceptibility to the majority of the tested antifungal agents.FDA-approved antifungal drugs, i.e., luliconazole, efinaconazole, and lanoconazole, showed the highest antifungal activity and should be promising candidates for the treatment of dermatophytosis caused by M. canis. However, their therapeutic effectiveness remains to be determined in clinical settings. This article is protected by copyright. All rights reserved.